JP2020509018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509018A5 JP2020509018A5 JP2019547077A JP2019547077A JP2020509018A5 JP 2020509018 A5 JP2020509018 A5 JP 2020509018A5 JP 2019547077 A JP2019547077 A JP 2019547077A JP 2019547077 A JP2019547077 A JP 2019547077A JP 2020509018 A5 JP2020509018 A5 JP 2020509018A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- acting
- long
- combination according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 239000000556 agonist Substances 0.000 claims description 37
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 102000000588 Interleukin-2 Human genes 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 125000003827 glycol group Chemical group 0.000 claims description 11
- 230000000717 retained effect Effects 0.000 claims description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 108700025316 aldesleukin Proteins 0.000 claims description 4
- 229960005310 aldesleukin Drugs 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 239000012636 effector Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465506P | 2017-03-01 | 2017-03-01 | |
| US62/465,506 | 2017-03-01 | ||
| US201762480971P | 2017-04-03 | 2017-04-03 | |
| US62/480,971 | 2017-04-03 | ||
| PCT/US2018/020514 WO2018160877A1 (en) | 2017-03-01 | 2018-03-01 | Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020509018A JP2020509018A (ja) | 2020-03-26 |
| JP2020509018A5 true JP2020509018A5 (enExample) | 2021-04-08 |
Family
ID=63371348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547077A Pending JP2020509018A (ja) | 2017-03-01 | 2018-03-01 | 養子細胞移植療法と併せてインターロイキン−２受容体α，β−選択的作動薬を用いる免疫療法的治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11318164B2 (enExample) |
| EP (1) | EP3589303A4 (enExample) |
| JP (1) | JP2020509018A (enExample) |
| KR (1) | KR20190121773A (enExample) |
| CN (1) | CN110366421A (enExample) |
| AU (1) | AU2018227810A1 (enExample) |
| CA (1) | CA3055040A1 (enExample) |
| IL (1) | IL269015A (enExample) |
| MX (1) | MX2019010382A (enExample) |
| WO (1) | WO2018160877A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2022260916A1 (en) * | 2021-06-08 | 2022-12-15 | Merck Sharp & Dohme Llc | Functional cell-based potency assay for measuring biological activity of interleukin 2 (il-2) analogs |
| CN116036243B (zh) * | 2022-04-20 | 2026-03-24 | 北京大学宁波海洋药物研究院 | 受体偏向的peg化il-2变体组合及其应用 |
| JP7847529B2 (ja) | 2022-11-04 | 2026-04-17 | ルネサスエレクトロニクス株式会社 | 回路、及び波形センサ |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| CA2611823C (en) * | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| PT3134123T (pt) * | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| EP3698850A1 (en) * | 2014-03-20 | 2020-08-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
| EP3034092A1 (en) * | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| AU2018205234B2 (en) * | 2017-01-06 | 2024-09-19 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists |
-
2018
- 2018-03-01 US US16/490,443 patent/US11318164B2/en not_active Expired - Fee Related
- 2018-03-01 CA CA3055040A patent/CA3055040A1/en active Pending
- 2018-03-01 KR KR1020197024673A patent/KR20190121773A/ko not_active Ceased
- 2018-03-01 MX MX2019010382A patent/MX2019010382A/es unknown
- 2018-03-01 WO PCT/US2018/020514 patent/WO2018160877A1/en not_active Ceased
- 2018-03-01 CN CN201880014971.8A patent/CN110366421A/zh active Pending
- 2018-03-01 EP EP18760525.8A patent/EP3589303A4/en not_active Withdrawn
- 2018-03-01 AU AU2018227810A patent/AU2018227810A1/en not_active Abandoned
- 2018-03-01 JP JP2019547077A patent/JP2020509018A/ja active Pending
-
2019
- 2019-08-29 IL IL26901519A patent/IL269015A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534308A5 (enExample) | ||
| JP2006508091A5 (enExample) | ||
| IL274584B1 (en) | Til expansion from fine needle aspirates and small biopsies | |
| DE69834494T2 (de) | Vorrichtung zur induktion einer ctl-antwort | |
| JP2021503281A5 (enExample) | ||
| JP2022506586A5 (enExample) | ||
| JP2013532153A5 (enExample) | ||
| RU2013121571A (ru) | Композиции и способы профилактики и лечения злокачественных новообразований | |
| JP2011530597A5 (enExample) | ||
| JP2015516496A5 (enExample) | ||
| JP2013536157A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2015107945A5 (enExample) | ||
| SG175895A1 (en) | Antitumor combination including ave8062 and sorafenib | |
| JP2010507584A (ja) | 細胞外マトリックス癌ワクチンアジュバント | |
| JP2018530568A5 (enExample) | ||
| CN113440533B (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| CN103861107A (zh) | 一种药物组合物及其用途 | |
| CN112535735A (zh) | 一种可同时放大免疫原性细胞死亡以及增强抗肿瘤效果的联合用药物 | |
| CN105169379A (zh) | 一种用于治疗胃癌的肿瘤疫苗及其制备方法 | |
| JP2019508056A5 (enExample) | ||
| Ballen et al. | Cellular immune therapy for refractory cancers: novel therapeutic strategies | |
| CN119074639A (zh) | 一种GelMA水凝胶复合材料及其制备方法和应用 | |
| CN113117088A (zh) | 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用 | |
| CN104086548B (zh) | 一种苦参碱衍生物及其应用 |